News Release Details
Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose
Opiant licensed exclusive global rights for the development and commercialization of drinabant for the emergency treatment of ACO from
“There is an urgent need for a product for the rapid reversal of ACO, and the extensive safety data of orally administered drinabant are encouraging regarding the prospects of an injectable version of the drug to better meet this need in the ER,” said
“During 2020, we expected to incur approximately
ACO is most often linked to the ingestion of edible products containing large quantities of delta9-tetrahydrocannabinol (THC), as well as the use of synthetic cannabinoids. ACO is characterized by panic and anxiety, feelings of paranoia, agitation, visual and auditory hallucinations, and nausea, and these last several hours to days. There are no
About Opiant Pharmaceuticals, Inc.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on March 21, 2019, including under the caption titled "Risk Factors." These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Investor Relations Contact:
Source: Opiant Pharmaceuticals, Inc.